Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?

Executive Summary

Novartis is teaming up with Allergan in a bid to get a treatment on the market for the fatty liver disease NASH, which currently has no approved treatments. The decision by Novartis to test its lead FXR agonist with Allergan's cenicriviroc (CVC) is interesting because Allergan's product reported mixed Phase II data.

Advertisement

Related Content

Intercept Boosts NASH Commercial Potential Via NICE Rare Disease Move
Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel